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Molecular mechanisms of tirapazamine (SR 4233, WIN 59075)-induced
hepatocyte toxicity under low oxygen concentrations
S Khan and PJ O'Brien
Faculty ofPharmacy, University of Toronto, 19 Russell Street, Toronto, Ontario MSS 2S2, Canada.
Summary Previously we showed that tirapazamine (SR 4233, Win 59075) is cytotoxic towards hepatocytes
under conditions of hypoxia but not in 10% or 95% oxygen and that bioreduction by DT-diaphorase or
cytochrome P450 is not a major pathway. In the present study, we report that tirapazamine is highly cytotoxic
to isolated rat hepatocytes maintained under 1% oxygen and the molecular cytotoxic mechanism has been
elucidated. Cytotoxicity was prevented by the cytochrome P450 2EI inhibitors phenyl imidazole, isoniazid,
isopropanol or ethanol, suggesting that cytochrome P450 2EI catalysed tirapazamine reductive bioactivation.
By contrast, dicoumarol, a DT-diaphorase inhibitor, markedly increased tirapazamine-induced cytotoxicity.
Cytotoxicity was also inhibited in normal but not DT-diaphorase-inactivated hepatocytes by increasing cellular
NADH levels with lactate or ethanol or the mitochondrial respiratory inhibitors. Evidence that oxygen
activation contributed to cytotoxicity was that glutathione oxidation occurred well before cytotoxicity ensued
and that tirapazamine was more cytotoxic towards catalase- or glutathione reductase-inactivated hepatocytes.
Furthermore, polyphenolic antioxidants such as quercetin, caffeic acid or purpurogallin, the radical trap
Tempol or the iron chelator desferrioxamine prevented tirapazamine-mediated cytotoxicity. However, the
antioxidants diphenylphenylenediamine, butylated hydroxyanisole or butylated hydroxytoluene did not prevent
cytotoxicity and malonaldehyde formation was not increased, suggesting that lipid peroxidation was not
important. The above results suggest that DT-diaphorase detoxifies tirapazamine whereas reduced cytochrome
P450 reduces tirapazamine to a nitrogen oxide anion radical which forms cytotoxic reactive oxygen species as
a result of redox cycling.
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Presently tirapazamine (3-amino-1, 2, 4-benzotriazine-1,4-di-
N-oxide) is in clinical trials as a potential anti-tumour agent.
It has been shown to be a highly selective hypoxic cell
cytotoxin (Zeman et al., 1986, 1989). It is also an effective
anti-tumour agent in vivo in combination with radiation
(Zeman et al., 1988) or compounds which enhance tumour
hypoxia (Brown, 1987). However subcapsular necrosis of the
liver, necrosis of the kidney medulla and olfactory epithelium
and bone marrow toxicity have been reported in rats after
acute dosing with tirapazamine at 0.3 mmol kg '(White et
al., 1992). Liver necrosis was confined to hepatocytes of the
centrilobular zone (zone 3) which normally experience low
oxygen tensions of 1-3% (White et al., 1992). Recently, it
has been confirmed that the toxicity of tirapazamine to
Chinese hamster fibroblasts does not level off at high oxygen
concentrations but continues to decrease as the oxygen con-
centrations increases (Koch, 1993). The hypoxic cytotoxicity
ratio (HCR) for tirapazamine is 50-200 (Zeman et al.,
1986).
The molecular mechanism of tirapazamine cytotoxicity is
believed to result from reductive bioactivation to cytotoxic
radical intermediate (Baker et al., 1988; Costa et al., 1989;
Laderoute et al., 1988) and evidence for a nitroxide radical
was obtained by electron spin resonance spectroscopy (Lloyd
et al., 1991). Enzymology studies with liver microsomes and
NADPH have implicated cytochrome P450 and NADPH-
cytochrome P450 reductase as the major hepatic reductases
responsible for the reductive bioactivation of tirapazamine
(Walton and Workman, 1990; Walton et al., 1992; Riley et
al., 1993). Previously, using isolated rat hepatocytes as a
non-proliferating model target cell and plasma membrane
damage as the cytotoxic end point, we concluded that DT-
diaphorase or reduced cytochrome P450 are not significantly
involved in tirapazamine bioreduction in hypoxic hepatocytes
(Silva and O'Brien, 1993). In the following we report that
tirapazamine is just as cytotoxic to hepatocytes under 1%
oxygen as was previously observed under nitrogen. Further-
more, in hepatocytes under 1% oxygen, tirapazamine was
detoxified by DT-diaphorase and activated by cytochrome
P450 2E1 as a result of a redox cycling-mediated oxygen
activation. We also report for the first time that hepatocyte
toxicity is prevented by the ferric chelator desferrioxamine,
superoxide dismutase mimics and polyphenolic antioxidants
that scavenge reactive oxygen species.
Materials and methods
Chemicals
Tirapazamine was a gift from Dr AM Rauth, Ontario
Cancer Institute, Toronto, Ontario, Canada. Antimycin A,
1-bromoheptane, caffeic acid, cimetidine, dicoumarol dithio-
threitol (DTT), erythromycin, reduced glutathione (GSH),
oxidised glutathione (GSSG), isoniazid, lactic acid, metyra-
pone, myxothiazol, potassium cyanide, sodium azide and
Tempol were obtained from Sigma (St Louis, MO, USA).
1-Phenylimidazole, purpurogallin, quercetin and trypan blue
were obtained from Aldrich (Milwaukee, WI, USA). Desfer-
rioxamine was a gift from Ciba Geigy Canada (Toronto,
Ontario, Canada). N,N-bis(z-chloroethyl)-N-nitrosourea
(BCNU) was a gift from Bristol-Myers (Syracuse, NY,
USA). SKF-525A was a gift from Smith Kline Beecham
(Oakville, Ontario, Canada). Collagenase (from Clostridum
histolyticum) and HEPES were purchased from Boehringer-
Mannheim (Montreal, PQ, Canada). High-performance
liquid chromatography (HPLC)-grade solvents were purchas-
ed from Calden (Georgetown, Ontario, Canada). All other
chemicals used were of analytical grade.
Animals
Male Sprague-Dawley rats (body weight 250-300g) fed a
standard chow diet and tap water ad libitum were used to
prepare hepatocytes.
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Isolation and incubation ofhepatocytes
The cells were isolated by collagenase perfusion of the liver
as described by Moldeus et al. (1978). Routinely, 85-95% of
the freshly isolated hepatocytes excluded trypan blue (trypan
blue final concentration 0.2%). The cells (1 x 106cells ml-')
were incubated in Krebs-Henseleit bicarbonate buffer (pH
7.4) supplemented with 12.5 mM HEPES under an atmo-
sphere of 1% oxygen, 94% nitrogen and 5% carbon dioxide
in 50 ml round-bottom flasks fitted on a standard-taper distil-
lation adaptor for five flasks which was rotated (30 r.p.m.) on
a rotary evaporator. The evaporator was positioned so that
the axis of rotation deviated 45° from the water surface so
that the flasks were immersed in the thermostated water. The
gas mixture was supplied continuously to the surface of the
incubation medium through the central vacuum exit of the
evaporator. The oxygen level was monitored continuously
with an oxygen electrode in the hepatocyte suspension and
was 1.0 ± 0.02% (10.5 ± I1Mm).
Tirapazamine was dissolved in dimethyl sulphoxide and
added in a final concentration of 0.2% (v/v). The control
incubation contained 0.2% (v/v) dimethyl sulphoxide alone.
Glutathione-depleted hepatocytes were obtained by prein-
cubating hepatocytes with 1-bromoheptane (200ptM) as pre-
viously described (Khan and O'Brien, 1991). To inactivate
hepatocyte catalase (EC 1.11.1.6) and glutathione reductase
(EC 1.6.4.2), sodium azide (final concentration 4mM) and
BCNU (final concentration, 501M) were added respectively
to the cells 20 min before the start of the experiment (Babson
and Reed, 1978; Rossi et al., 1989). Azide and BCNU were
not cytotoxic at these concentrations over a 4 h incubation
period. To inactivate various cytochrome P450 isoenzymes,
SKF-525A, ethanol, isopropanol, 1-phenylimidazole, isoni-
azid, metyrapone, cimetidine or erythromycin was added to
the cells 10 min before the start of the experiment (Netter,
1962; Wrighton et al., 1985; Quan et al., 1992; Riley et al.,
1993). To inactivate DT-diaphorase, hepatocytes were prein-
cubated with dicoumarol (final concentration 2511M) for
10 min (Ernster et al., 1960; Rossi et al., 1989). Various
antioxidants, radical scavengers, desferrioxamine (ferric ion
chelator), artificial electron acceptors, DTT or mitochondrial
electron transport chain inhibitors were preincubated for
5 min before the start of the experiment. All enzyme
modifiers or other inhibitors were maintained in the cell
medium throughout the experiment and were not cytotoxic at
the concentrations used.
Assays
Hepatocyte viability was assessed by the trypan blue dye
exclusion test in a Neubaur chamber by light microscopy.
Viability; was examined immediately after isolation, and at
various time points during the experiment.
Total GSH and GSSG in the hepatocytes were measured
by HPLC analysis in deproteinated samples (5% metaphos-
phoric acid) after derivatisation with iodoacetic acid and
1-fluoro-2,4-dinitrobenzene using a it-Bondapak NH2 column
(Waters, Mississauga, Ontario, Canada) as described by Reed
et al. (1980). GSH and GSSG were used as external stan-
dards. A Waters model 6000A solvent-delivery system equip-
ped with a Waters model 660 solvent programmer, a WISP
710A automatic injector and a data module was used for
analysis.
Statistics
Statistically significant differences between control and ex-
perimental groups were obtained using Student's t-test. The
minimal level of significance chosen was P<0.05.
Results
As shown in Figure 1, tirapazamine (190 LAM) added to hepa-
tocytes maintained under 1% oxygen/94% nitrogen/5% car-
bon dioxide caused 50% cytotoxicity within a 2 h incubation
period. Untreated hepatocytes retained their viability under
these conditions. The effect of various cytochrome P450
inhibitors on tirapazamine-induced cytotoxicity is presented
in Table I. Cytochrome P450 2E1 inhibitors I-phenylimid-
azole, isoniazid, isopropanol and ethanol were cytoprotective,
whereas other cytochrome P450 inhibitors, metyrapone,
SKF-525A, cimetidine and erythromycin, did not prevent
tirapazamine-induced cytotoxicity. As shown in Figure 2,
dicoumarol, a highly effective inhibitor of DT-diaphorase,
increased the tirapazamine-dependent cytotoxicity at least
2-fold. None of the cytochrome P450 inhibitors or dico-
umarol affected the viability of hepatocytes in the absence of
tirapazamine. The rate of tirapazamine disappearance (2.1
nmol min-' 10-6 cells) in hepatocytes under 1% oxygen was
a little slower than that found under a hypoxic environment
(Silva and O'Brien, 1993).
Tirapazamine cytotoxicity was also prevented by increasing
cytosolic NADH levels (Sood and O'Brien, 1994) by the
addition of lactate or ethanol (Figure 2). This cytoprotection
was prevented if hepatocyte DT-diaphorase was inhibited by
dicoumarol (Figure 2). Cytotoxicity caused by tirapazamine
was also markedly decreased by increasing hepatocyte cyto-
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Figure 1 (a) Increased susceptibility of GSH-depleted cells to
tirapazamine. Hepatocytes were incubated alone (--x--), with
190gLM tirapazamine (0) or with DTT (5 mM) at 10 min +
tirapazamine (190tiM) (A). (A) GSH-depleted cells; (-) with
tirapazamine (190I1M). Three separate experiments were carried
out. Points, mean; bars, s.e. (b) Increased susceptibility of GSH
reductase- (BCNU pretreated) or catalase (sodium azide pre-
treated)-inactivated cells to tirapazamine. Hepatocytes were
incubated alone (--x--), with tirapazamine (190 tM) (0), with
azide (4 mM) + tirapazamine (190glM) (A), with BCNU
(50 ttM) + tirapazamine (190IM) (-) with azide (4mM) (U) or
with BCNU (50I1M) (0). Three separate experiments were car-
ried out. Points, mean; bars, s.e.
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Table I Effect of various cytochrome P450 inhibitors on SR 4233-induced
cytotoxicity
Cytotoxicity
(per cent trypan blue uptake)
(min)
Treatment 30 60 120 180
None 16±3 17±3 19±3 21±4
SR 4233 (190IM) 29±4 38±4 54±5 81±6a
SR 4233 (190gM) plus
Ethanol (10mM) 21±3 29±3 30±3 44±4b
Isopropanol (2mM) 23±3 29±3 35±4 43±4b
I-Phenylimidazole (0.3 mM) 20±3 28±3 29±4 45±4b
Isoniazid (5 mM) 24±3 27±3 36±4 42±4b
Metyrapone (1 mM) 31±3 42±4 54±4 74±6
SKF-525A (0.OSmM) 32±3 41±2 62±3 84±7
Cimetidine (0.O5mM) 31±4 39±4 44±5 79±6
Erythromycin (0.5 mM) 30±4 38±4 45±4 69±6
Values are expressed as means of the three separate experiments (±s.d.).
aSignificant difference in comparison with control (P<0.001). bSignificantly
decreased in comparison with SR4233 treated (P<0.001).
solic NADH levels (Sood and O'Brien, 1994) using the mito-
chondrial respiratory inhibitors antimycin A, myxothiazol or
cyanide at concentrations which did not affect cytotoxicity
(Table II).
Hepatocytes were considerably more sensitive to tirapaz-
amine when the cell's defence system against oxidative stress
was compromised by inactivating hepatocyte catalase or
glutathione reductase with azide or BCNU respectively
beforehand. As shown in Figure lb, tirapazamine (190I1M)
incubated with catalse- or glutathione reductase-inactivated
hepatocytes caused 100% and 76% cytotoxicity respectively
in 120 min. GSH depleted hepatocytes were much more
susceptible to tirapazamine (190ItM) with 100% cytotoxicity
at 2 h. DTT, a disulphide reductant, prevented tirapazamine-
induced hepatocyte cytotoxicity (Figure la).
The phenolic antioxidants BHA or BHT and DPPD did
not affect tirapazamine-dependent cytotoxicity (Table III)
and tirapazamine did not increase malondialdehyde (thiobar-
bituric acid reactants) formation, indicating that little lipid
peroxidation formation had occurred (results not shown).
However, cytotoxicity was effectively prevented by a spin
radical trap Tempol or the ferric ion chelator, desferriox-
amine (Table III). Furthermore, tirapazamine-induced cyto-
toxicity and GSH oxidation was also prevented by the
polyphenolic antioxidants quercetin, purpurogallin and
caffeic acid (Table III).
As shown in Figure 3, tirapazamine incubated with GSH
reductase-inactivated hepatocytes caused GSH oxidation to
GSSG before the cytotoxicity ensued. GSH oxidation was
prevented by the polyphenolic antioxidants quercetin (Figure
3), purpurogallin and caffeic acid and by the ferric ion
chelator desferrioxamine (results not shown). Furthermore,
hepatocyte GSH oxidation to GSSG was prevented by inhib-
iting cytochrome P450 with phenylimidazole and enhanced
by inhibiting DT-diaphorase with dicoumarol (Figure 3).
Discussion
The clinical effectiveness oftirapazamine may be governed by
a number of physiological and biochemical differences
between hypoxic and normal tissues. Differences in oxygen
tension as well as the relative reductase levels in the various
zones of the liver may profoundly influence the effectiveness
of the drug. In the present study we report that tirapazamine
was as cytotoxic to isolated rat hepatocytes in the presence of
a low oxygen concentration (1% oxygen) as reported pre-
viously under hypoxic conditions (Silva and O'Brien, 1993).
Furthermore, tirapazamine was not toxic to hepatocytes
maintained under 10% oxygen or 95% oxygen presumably
because at high oxygen concentration the hepatocytes more
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Figure 2 DT-diaphorase inactivation (pretreated with 25 iLM di-
coumarol) increased susceptibility to tirapazamine, and increasing
the NADH levels in cells (addition of 1Omm lactate) prevented
tirapazamine-induced cell death. Hepatocytes were incubated
alone (--x--) or with tirapazamine (190 JM) (0), with dicoumarol
(25 aM) (A), with dicoumarol (25gM) + tirapazamine (190IM)
(0), with lactate (OmM))+ tirapazamine (190gM) (A) or with
lactate (10 mM) + tirapazamine (190jsM) + dicoumarol (25 lsM)
(M). Three separate experiments were carried out. Points, mean;
bars, s.e.
readily detoxify tirapazamine radicals or reactive oxygen
species (Silva and O'Brien, 1993).
Previously, we reported that cytochrome P450 reductase
but not cytochrome P450 or DT-diaphorase seems to be
important for tirapazamine bioactivation in hepatocytes
under a hypoxic atmosphere (Silva and O'Brien, 1993). How-
ever, tirapazamine-induced cytotoxicity to hepatocytes main-
tained under 1% oxygen was prevented by cytochrome P450
2E1 substrates or the inhibitors phenylimidazole, isoniazid,
isopropanol or ethanol. Oxidation of hepatocyte GSH was
also prevented by the cytochrome P450 2E1 inhibitors.
Inhibitors of other cytochrome P450 isoenzymes, such as
SKF 525A, metyrapone, cimetidine or erythromycin, were
not cytoprotective. This suggests that under 1% oxygen
782Mechanism of trapazamin-induced cytotoxicity
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Table II Prevention of SR 4233-induced cytotoxicity by mitochondrial
electron transport chain inhibitors
Cytotoxicity
(per cent trypan blue uptake)
(min)
Treatment 30 60 120 180
None 16±3 17±3 19±3 21±4
SR 4233 (190gM) 29±4 41±4 58±5 86±6a
SR 4233 (190ytM) plus
Antimycin A (I M) 21±3 25±3 30±3 45±4b
Myxothiazol (0.1 M) 24±3 32±3 34±4 43±4b
Cyanide (200PM) 24±3 29±3 37±4 52±4b
Antimycin A (IgM) 22±3 26±3 28±4 30±4
Myxothiazol (0.1 tM) 24±3 26±3 31±4 34±4
Cyanide (200gM) 27±3 31±3 32±4 35±4
Values are expressed as means of the three separate experiments (± s.d.).
aSignificant difference in comparison with aerobic control (P<0.001).
bSignificantly decreased in comparison with SR 4233 treated (P<0.001).
Table III Prevention ofSR4233 cytotoxicity by radical scavengers ora ferric
ion chelator
Cytotoxicity
(per cent trypan blue uptake)
(min)
Treatment 30 60 120 180
None 16±3 17±3 19±3 21 ±4
SR 4233 (190IgM) 29±4 39±4 55±5 81±6a
SR 4233 (190gM) plus
Tempol (0.3mM) 21±3 25±3 34±3 36±4b
Quercetin (0.1 mM) 23±3 28±3 33±4 35±4b
Purpurogallin (0.1 mM) 24±3 31±3 33±4 34±4b
Caffeic acid (0.3 mM) 23±3 36±3 42±4 47±4b
Desferal (0.5 mM) 22±3 26±3 38±4 40±4b
BHA (50gM) 28±3 37±4 51±4 78±6
BHT (50jiM) 29±3 38±3 49±5 77±6
DPPD (20 M) 30±3 36±4 50±5 79±7
Values are expressed as means of the three separate experiments (±s.d.).
aSignificant difference in comparison with control (P<0.001). bSignificantly
decreased in comparison with SR 4233 treated (P<0.001).
reduced cytochrome P450 2E1 is more effective than cyto-
chrome P450 reductase at carrying out a one-electron bio-
reduction of tirapazamine to the tirapazamine radical which
redox cycles and forms cytotoxic reactive oxygen species
(ROS). Studies using rat/mouse liver microsomes or tumour
cells have also shown that tirapazamine can undergo a one-
electron bioreduction by various enzymes including cyto-
chrome P450 reductase and cyp2b, cyp2c, and/or cyp3c cyto-
chrome P450 subfamilies (Walton et al., 1989; Cahil and
White, 1990; Walton and Workman, 1990; Beiderman et al.,
1991; Lloyd et al., 1991; Riley et al., 1993; Wang et al.,
1993). This generates a free radical which may exert its
cytotoxic effects through DNA single- and double-strand
breaks, probably as a result of hydrogen abstraction, but not
by direct binding to DNA (Baker et al., 1988; Laderoute et
al., 1988; Costa et al., 1989). The centrilobular location of
the hepatic necrosis induced by tirapazamine in rats (White
et al., 1992) could therefore be explained by the low oxygen
concentration in this liver zone (Kessler et al., 1973). Cytoch-
rome P450 2E1 is also located in the centrilobular zone of
the liver (Anundi et al., 1993) and would be more reductive
at low oxygen concentrations. Recently, reduced cytochrome
P450 2B1 was found to catalyse a one-electron bioreduction
of adriamycin (Goeptar et al., 1993).
DT-diaphorase inactivated hepatocytes were much more
susceptible to tirapazamine under 1% oxygen than control
hepatocytes. Furthermore, increasing NADH levels in hepa-
tocytes (Sood and O'Brien, 1994) with lactate or ethanol or
by partly inhibiting hepatocyte respiration with the mito-
chondrial electron transport chain inhibitors myxothiazol,
antimycin A or cyanide prevented tirapazamine-induced cyto-
toxicity. Cytoprotection by lactate was also prevented by
inhibting DT-diaphorase. This suggests that DT-diaphorase
in intact cells detoxifies tirapazamine presumably as a result
of a two- or four-electron bioreduction. We previously show-
ed that the two electron as well as four-electron reduction
products of tirapazamine, i.e. SR 4317 and SR 4330 respec-
tively, are formed in intact hypoxic hepatocytes but are not
toxic to cells. Recently, Riley and Workman (1992) showed
that DT-diaphorase purified from Walker 256 rat tumour
cells catalyses in vitro a direct two- and four-electron reduc-
tion of tirapazamine.
Reactive oxygen species (ROS) seem to be involved in the
tirapazamine cytotoxic mechanisms(s) even at low oxygen
concentrations as tirapazamine was also much more cyto-
toxic to catalase or glutathione reductase-inactivated hepa-
tocytes. Furthermore, GSH oxidation to GSSG readily
occurred in GSH reductase-inactivated hepatocytes well
before cytotoxicity ensued. Also, GSH oxidation was enhanc-
ed when DT-diaphorase was inactivated with dicoumarol and
prevented when cytochrome P450 2E1 was inhibited with
phenylimidazole. Furthermore, Tempol, which can act as a
radical trap or superoxide dismutase mimic (Gelven et al.,
1991) or desferrioxamine, a ferric iron chelator, prevented
hepatocyte cytotoxicity suggesting the involvement of ferric
ion in the formation of ROS. Cytotoxicity and GSH oxida-
tion was also prevented by the polyphenolic antioxidants
quercetin, purpurogallin and caffeic acid, which scavenge
superoxide radicals (Marklund and Marklund, 1974; Robak
and Gryglewski, 1988) and form ferric ion complexes
(Krishna et al., 1992).
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a and butylated hydroxytoluene, which are excellent at prevent-
ing lipid peroxidation but poor at scavenging reactive oxygen
species (Robek and Gryglewski, 1988), were not cytoprotec-
tive. Furthermore, no malondialdehyde formation was detect-
ed, which suggests that lipid peroxidation was not critical to
the tirapazamine cytotoxic mechanism and that membrane
phospholipids are not important cytotoxic targets for either
the tirapazamine nitroxide free radical or ROS.
Membrane protein thiols may be important cytotoxic tar-
gets as a result of mixed protein disulphide formation by the
intracellular GSSG formed early on in tirapazamine-induced
cytotoxicity. Thus, the mixed protein disulphide reductant
dithiothreitol restored GSH levels (data not shown) and
prevented tirapazamine-induced cytotoxicity even when add-
ed 10min after the addition of tirapazamine. Oxidation of
membrane protein thiols by ROS to sulphenic acid would
also explain why tirapazamine was much more cytotoxic to
GSH-depleted hepatocytes. ROS may only be cytotoxic if
generated at the membrane and would therefore require
0 30 60 90 120 diffusion of the tirapazamine radical from its site of genera-
tion by the endoplasmic reticular cytochrome P450 2E1. This
b would be more likely to occur at 1% oxygen than at 10% or
r.n 20% oxygen and could be another explanation for
tirapazamine cytotoxicity at 1% oxygen.
Taken together, the results from the present study suggest
that in intact hepatocytes at 1% oxygen the bioreduction of
tirapazamine by two or four electrons by DT-diaphorase is a
detoxification pathway but that the one-electron bioreduction
Figure 3 GSH depletion (a) and GSSG formation (b) induced by
tirapazamine in glutathione reductase-inactivated isolated hepa-
tocytes. Hepatocytes were incubated alone (--x--) or with
tirapazamine 190gM (0), with phenylimidazole (300 gM) + tirap-
azamine (190 gM) (@), with quercetin (100 ltM) + tirapazamine
(190 tMm) (A) and with dicoumarol (25 gM) + tirapazamine
0 30 60 90 120 (190gM) (A). Three separate experiments were carried out.
Time (min) Points, mean; bars, s.e.
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Figure 4 Proposed mechanism(s) of tirapazamine-induced cytotoxocity in isolated rat hepatocytes.
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of tirapazamine by reduced cytochrome P450 results in the
formation of cytotoxic reactive oxygen species as a result of
futile redox cycling (Figure 4). Hepatocyte cytotoxicity could
be prevented by cytochrome P450 2E1 inhibitors, NADH-
generating substrates, superoxide dismutase mimics, poly-
phenolic antioxidants or ferric chelators. Therefore, poly-
phenolic antioxidants or ferric chelators could prove useful
therapeutically in preventing tirapazamine toxicity.
Abbreviations: BCNU, N,N-bis(2-chloroethyl)-N-nitrosourea; BHA,
butylated hydroxyanisole; BHT, butylated hydroxytoluene; DMSO,
dimethyl sulphoxide; DPPD, N,N-diphenyl-1,4-phenylenediamine;
DTT, dithiothreitol; EGTA, ethylene glycol-bis-(fi-aminoethyl ether)-
N,N,N',N'-tetraacetic acid; GSH, reduced glutathione; GSSG, oxidis-
ed glutathione; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesul-
phonic acid; ROS, reactive oxygen species; s.d., standard devia-
tion.
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